Eckert & Ziegler Q3/2016: Rise in Radiopharma segment income keeps the Group on track. Positive outlook for 2017.
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarterly / Interim Statement/9-month figures Berlin, 3 November 2016. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700), a specialist for isotope-based applications in medicine, science and industry headquartered in Berlin, achieved sales of EUR 103.1 million in the nine months from January to September 2016. The sales figures were almost exactly on par with the prior-year level of EUR 102.7 million. Currency effects and acquisitions did not play much of a role; the slight was largely based on organic growth. The sharpest rise in sales of EUR 3.0 million, or 12 %, to EUR 29.3 million was posted by the Radiopharma segment due to the continuing growth of pharmaceutical radioisotopes. The Isotope Products segment saw sales rise by EUR 1.2 million, or 2 %, to EUR 58.2 million. As expected, sales in the Radiation Therapy segment, on the other hand, declined by EUR 3.9 million, or 18 %, to EUR 17.8 million following the prior year's disposal of two divisions. Group earnings per share fell by EUR 0.27, or 19 %, year on year to EUR 1.43. This amount is slightly higher than planned; as a result, the Executive Board is confident that earnings per share for the full year will amount to EUR 1.80 as forecast. Eliminating the losses for 2016 that arose from the winding-down of a Californian subsidiary, earnings per share amounted to EUR 1.47, that is to say EUR 0.04 more per share. The scheduled decline in profits by nearly 20% was due to the EUR 6.4 million drop in extraordinary income which stood at a record figure of EUR 8.8 million in the prior year as a result of, among other things, the sale of an investment (OctreoPharm Sciences). Excluding extraordinary effects and the financial result for both periods, and including the discontinued operations, there has been a significant improvement in the results of operations. While sales remained more or less unchanged, the Group's gross margin rose by EUR 2.1 million and administrative and selling expenses fell by EUR 3.0 million. The disposals of loss-bringer operations and the closure of unprofitable subsidiaries enabled the Group to reduce its cost base by a total of EUR 5.4 million, or 5 % of sales, within a period of twelve months. In 2017 earnings are expected to grow and could exceed EUR 2.00 per share, assuming that exchange rates remain stable and excluding acquisitions and the sale of divisions. Sales of just under EUR 150 million are expected. The complete quarterly financial statements can be viewed under: About Eckert & Ziegler. Your contact:
2016-11-03 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English | |
Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG | |
Robert-Rössle-Str.10 | ||
13125 Berlin | ||
Germany | ||
Phone: | 49 30 941084-138 | |
Fax: | 49 30 941084-112 | |
E-mail: | karolin.riehle@ezag.de | |
Internet: | www.ezag.de | |
ISIN: | DE0005659700 | |
WKN: | 565970 | |
Listed: | Regulated Market in Frankfurt (Prime Standard), Stuttgart; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Tradegate Exchange | |
End of News | DGAP News Service |